RxDoctor Payments Data

Sherlyana Helen, MD

Family Medicine · Pittsburgh, PANPI 1528388238

Payments from drug & device makers

$2,790in general payments, 2019–2025

Across 153 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$637
  • GSK$470
  • Pfizer$371
  • AbbVie$357
  • Amgen$217
  • Lilly USA, LLC$131
  • plus $607 from 13 others

What the payments were for

  • Food & beverage$2,75899%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,790 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$79,197
Medicare patients
144
Services billed
1,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$165,370
JardianceEmpagliflozin74$106,805
EliquisApixaban123$106,366
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$82,456
MyrbetriqMirabegron39$23,395
XareltoRivaroxaban29$22,550
FarxigaDapagliflozin Propanediol21$21,905
MounjaroTirzepatide17$20,125
ProliaDenosumab11$18,784
LinzessLinaclotide18$11,132
JanuviaSitagliptin Phosphate13$8,420
ShingrixVaricella-Zoster Ge/As01b/Pf31$6,842
Breo ElliptaFluticasone/Vilanterol15$5,986
Fluticasone-SalmeterolFluticasone Propion/Salmeterol45$4,696
Atorvastatin Calcium406$4,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$637$165,37093 claims
Boehringer IngelheimJardiance$87$106,80574 claims
PfizerEliquis$371$106,366123 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$470$95,285150 claims
AstraZenecaFarxiga$18$21,90521 claims
Lilly USA, LLCMounjaro$131$20,12517 claims
AmgenProlia$217$18,78411 claims
AbbVieLinzess$357$11,13218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →